Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NVT6d4ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXiOYMxNTFyIN88US=> NVnVcGpKOC12IHS= NXO3ZVR2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3SzZ|I3PzB{N{i0
HepG2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfISHoxNTFyIN88US=> NVm2T4h5OC12IHS= NHHkUWhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUTQTFFMOjZ5MEK3PFQ>
HT29 Mmr0SpVv[3Srb36gRZN{[Xl? Moi3OVDDqG6P NFPHenIzPC15MjDo NFvIVFBqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDR6wrDoxsA> MVqyOlcxOjd6NB?=
HepG2 MorOSpVv[3Srb36gRZN{[Xl? NYnUSGZNPTEEoH7N MmnENlQuPzJiaB?= MoTGbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkAzPMLiaNMg M3zKeVI3PzB{N{i0
HCC827 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\td|c2NzdwNT:xNEBvVQ>? M2P3XlczyqCq MXvEUXNQ NI[5PWdmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= NHHmVYIzPjZ5NUS4OC=>
A549  M1HkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfHNVAwOTVxMkCgcm0> NGXv[pA4OsLiaB?= NYn4SFFrTE2VTx?= M3zhSoVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk M4\wdVI3Pjd3NEi0
NCI-H460  M3ftWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXwNVAwOjBxM{Cgcm0> MVK3NuKhcA>? NH\TNnhFVVOR MUTlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? MYiyOlY4PTR6NB?=
J89GFP NXi1clRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW5bItvTE2VT9Mg M3m0bmVEPTB;NEmuPFUhyrFiMUKuOlUhdk1? MlzsNlY2PjN3Nki=
THP89GFP MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWySG1UV8Li MmLnSWM2OD1zOT6zOEDDuSB4LkSzJI5O MlPiNlY2PjN3Nki=
SK-NEP-1 NVTHOWY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOwMlAy6oDVMUCuNEDPxE1? M2DrPVI1KGh? M1HmSGROW00EoB?= NU\2OFR7UUN3ME23Ok4{PCCwTR?= NFn0fY8zPjF5NkKxPS=>
G401 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ftc|AvODIkgKOxNE4xKM7:TR?= MXOyOEBp M2HQNWROW00EoB?= M4DQOWlEPTB;MUSzMlAzKG6P MX2yOlE4PjJzOR?=
SK-NEP-1 NITIXXpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHHXSVg2OCCwTR?= NH7mWFYy6oDVNDDk NX\HZ3N[TE2VT9Mg MYXy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M3[yWVI3OTd4MkG5
G401 NX7IUIRPS2WubDDWbYFjcWyrdImgRZN{[Xl? NGDwTpY2OCCwTR?= NWfBdIp6OeLCk{Sg[C=> NXrjXGsyTE2VT9Mg MnrHdoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz MmXwNlYyPzZ{MUm=
SK-NEP-1 M{TwVWFxd3C2b4Ppd{BCe3OjeR?= NXOzfVBFPTBxMUCwJI5O M{X2W|I1KGh? MVXEUXNQyqB? NILoe|lqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWiyOlE4PjJzOR?=
G401 NUHV[3BiSXCxcITvd4l{KEG|c3H5 Mo\aOVAwOTByIH7N MUKyOEBp NEfwb|dFVVORwrC= NWDzeXpocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGLtUWszPjF5NkKxPS=>
SK-NEP-1 MVfGeY5kfGmxbjDBd5NigQ>? MYi1NE8yODBibl2= M4DHU|I1KGh? M1KwTmROW00EoB?= NEPN[5Z{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w M2HWbVI3OTd4MkG5
G401 NVL5W4xQTnWwY4Tpc44hSXO|YYm= NVTmcmNSPTBxMUCwJI5O NGPiZXEzPCCq NEfwTJdFVVORwrC= NVLafYU5e2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?= NEHNUmkzPjF5NkKxPS=>
SK-NEP-1 NV31PGU6TnWwY4Tpc44hSXO|YYm= NEjKRmg2OC9zMECgcm0> Mki1NlQhcA>? MoraSG1UV8Li MW\pcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> M3TtZlI3OTd4MkG5
G401 MWnGeY5kfGmxbjDBd5NigQ>? NInTcHQ2OC9zMECgcm0> MV2yOEBp NEeweo9FVVORwrC= NWPjbmMycW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? NWjPZ|gzOjZzN{[yNVk>
RPMI 8226 NFXFe|lE\WyuIGP1dpZqfmGuIFHzd4F6 NVPPVHhpOi92L{[gcm0> NYf3[Vh4PDkkgJno NH\YXWVqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MnXlNlYxODB{OUK=
OPM2 M4fXWGNmdGxiU4Xyeol3[WxiQYPzZZk> MkHUNk81NzZibl2= MnHjOFjjiImq MojZbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? NEnqVIozPjByMEK5Ni=>
U266 MUjD[YxtKFO3co\peoFtKEG|c3H5 Ml:zNk81NzZibl2= MoTNOFjjiImq NEPk[4ZqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NUHxfVM5OjZyMECyPVI>
H929 M1:xc2NmdGxiU4Xyeol3[WxiQYPzZZk> M1vUOFIwPC94IH7N MX:0PQKBkWh? NUT4fmZrcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= M3jsVVI3ODByMkmy
RPMI 8226  NV3MNmR7SXCxcITvd4l{KEG|c3H5 NWrveGhLPOLCiX7N NGnuOIYzPC92ODDo MmjtbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NYXMUIFmOjZyMECyPVI>
HCC827 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe3R2QyOCCwTR?= MYm0PEBp NEHjfoZFVVOR MVjlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? M1\nWFI2QTR2NkG3
NCI-H23 M4j3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS1VpExOTBibl2= MX[0PEBp NHvHXZBFVVOR MXjlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? MlG3NlU6PDR4MUe=
AML3 MUDGeY5kfGmxbjDBd5NigQ>? MkPMNE0yKM7:TR?= NXvmdGViOjUEoHi= NHHNXWpqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{DEcVI2PjF{OUSx
ML-1 MVnGeY5kfGmxbjDBd5NigQ>? Mk\zNE0yKM7:TR?= NHLWbFQzPMLiaB?= M1;hWYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn7CNlU3OTJ7NEG=
RPMI-8226vr10  MWjGeY5kfGmxbjDBd5NigQ>? MnHiNE0yKM7:TR?= M{fUOlI1yqCq NHH3O|NqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Ml7ENlU3OTJ7NEG=
ML-1 M2i2ZmZ2dmO2aX;uJGF{e2G7 M4XFOVEh|ryP MXyyOOKhcA>? MXnpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFQu\m:uZB?= NITnb2UzPTZzMkm0NS=>
RPMI-8226vr10  NEK4c5lHfW6ldHnvckBCe3OjeR?= NIP4R4YyKM7:TR?= NY\wZlhWOjUEoHi= MorJbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=> NXXWUJJHOjV4MUK5OFE>
SK-N-BE (2) MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nI[lI16oDLaB?= NYDh[YVnUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N NWqxW2x[OjV|MEi5NVY>
SK-N-BE (2), PAN  MK MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TGZVI16oDLaB?= M1:2c2lEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= NYPVcVRJOjV|MEi5NVY>
SK-N-BE (2), MK  PAN NFvnPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLRT2JyOjUkgJno Ml:3TWM2OD1|OEKuNQKBkcLz4pEJOFMvOiCwTR?= MWiyOVMxQDlzNh?=
SK-N-AS NFLPfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXhbVgzPOLCiXi= M3;2OGlEPTB;M{euNgKBkcLz4pEJNk41KG6P MXOyOVMxQDlzNh?=
SK-N-DZ NYCyfWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33CWVI16oDLaB?= NXrjZVd5UUN3ME2xO{4y6oDLwsJihKkxNjRibl2= M4\yfFI2OzB6OUG2
Caki-1 NVTOOHJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjQNVAwOjVxNUCgcm0> NG[4UHE1QCCq M3HtNYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= MUCyOVI4QTF7MR?=
ACHN NV3NR|RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrZcWFbOTBxMkWvOVAhdk1? M3LtNVQ5KGh? NFjKeJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NHL4O3kzPTJ5OUG5NS=>
769-P M3X4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjP[nlIOTBxMkWvOVAhdk1? M4i1OFQ5KGh? NHf2cGFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= Mk\QNlUzPzlzOUG=
786-O  M1fPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTvNVAwOjVxNUCgcm0> NI\mVoU1QCCq MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MnP6NlUzPzlzOUG=
Caki-1 M{D6XmFxd3C2b4Ppd{BCe3OjeR?= NWWxbGpMPTBibl2= MUO0PEBp MonPbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? MXGyOVI4QTF7MR?=
ACHN MYPBdI9xfG:|aYOgRZN{[Xl? NXLQZnpFPTBibl2= M3[xO|Q5KGh? M{jkNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ M{TE[VI2Ojd7MUmx
769-P M3TuTmFxd3C2b4Ppd{BCe3OjeR?= M2e1ZVUxKG6P Mn;IOFghcA>? M2XDXolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NGDHcFMzPTJ5OUG5NS=>
786-O  NXfNbHhFSXCxcITvd4l{KEG|c3H5 NWXGSnB7PTBibl2= Ml\LOFghcA>? MmTFbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? MkXmNlUzPzlzOUG=
Caki-1 NV7NfHBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PXPFI2NzVyIH7N MUm0PEBp MY\EUXNQ M4XVZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NFTDUVIzPTF5NkO1OC=>
ACHN M1L2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqyOU82OCCwTR?= Mm\oOFghcA>? NXnr[YtyTE2VTx?= MkHKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= M2nmXVI2OTd4M{W0
769-P M3T6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojDNlUwPTBibl2= NWfRcWI5PDhiaB?= NVqyVHg6TE2VTx?= M{nYd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NEHhPW0zPTF5NkO1OC=>
Caki-1 MW\Dc4xwdnliRn;ycYF1cW:wIFHzd4F6 Mm\lOVAhdk1? MlvYO{0yPCCm MVrEUXNQ NH\CUVB{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? NWLr[Vk1OjVzN{[zOVQ>
ACHN MoTQR49td267IF\vdo1ifGmxbjDBd5NigQ>? NYnSU49qPTBibl2= NFz2eYc4NTF2IHS= MX7EUXNQ MoDtd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MV6yOVE4PjN3NB?=
769-P MWfDc4xwdnliRn;ycYF1cW:wIFHzd4F6 MlTWOVAhdk1? MkXVO{0yPCCm M4Ttd2ROW09? M4n1e5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NYLW[2RlOjVzN{[zOVQ>
Caki-1 NGr0UXNCeG:ydH;zbZMhSXO|YYm= MVW1NEBvVQ>? MV[0PEBp M4TuVGROW09? NFHpdmVqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHL3U2UzPTF5NkO1OC=>
ACHN MonVRZBweHSxc3nzJGF{e2G7 MVq1NEBvVQ>? M3H1OFQ5KGh? M33FT2ROW09? MVnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXSyOVE4PjN3NB?=
769-P NX;TT4dXSXCxcITvd4l{KEG|c3H5 MX:1NEBvVQ>? MnGwOFghcA>? MWLEUXNQ NEDPWnZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4X5O|I2OTd4M{W0
MDA-MB-231 M4Psd21wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? M2C2W|ExyqCwTR?= M{SzPVPDqGR? NEP1Zo9FVVOR MWrhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? M1H6NFI1QDFyNEm3
BT-549 NWHzOXY1VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 NUDDcWZyOTEEoH7N NXy0S3g1O8LiZB?= NX;vVI5LTE2VTx?= MmPWZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NHXrfGMzPDhzMES5Oy=>
MCF-7  M1nyXm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NUfWS4hbOTEEoH7N MUSzxsBl NWjVUVF3TE2VTx?= NHjTUnRidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= NUW5ZYlbOjR6MUC0PVc>
MCF-7 M{LYT2Z2dmO2aX;uJGF{e2G7 NV65RVg6PS13MDDuUS=> M3P0S|I1KGh? MWLEUXNQ NVzyOVM{emWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>? NITGXYEzPDN4NkSwOy=>
CTS M{PBOWFxd3C2b4Ppd{BCe3OjeR?= M1\qclDjiJN2MDDuUeKh MUG0PEBp NXr6RpJXcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3jSbFI1OjR2NEK5
OCI-AML3  MoeyRZBweHSxc3nzJGF{e2G7 MYew5qCUPDBibl5CpC=> MX60PEBp MnLpbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{f2dVI1OjR2NEK5
U937 MXTBdI9xfG:|aYOgRZN{[Xl? M{XxVVDjiJN2MDDuUeKh MYe0PEBp MnLxbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFq2fmYzPDJ2NESyPS=>
PC3 MWnBdI9xfG:|aYOgRZN{[Xl? MoTmNE0yODBibl2= MlmzNlQwPDhiaB?= Mnr3bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHvWO5IzPDF4M{KzNC=>
PC3-AR NF;xdGZCeG:ydH;zbZMhSXO|YYm= M3PPbVAuOTByIH7N NVe2fWJyOjRxNEigbC=> MX;pcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUHNUHpPOjRzNkOyN|A>
PC3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\tcFAuOTByIH7N MYiyOE81QCCq MVrpcoR2[2W|IHHjZ5VufWyjdHnvckBw\iC|dXLHNUBxd3C3bHH0bY9v M33zNFI1OTZ|MkOw
PC3-AR M1vSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[0cGoxNTFyMDDuUS=> MkDjNlQwPDhiaB?= NUTBbVlxcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiC2aHWgS|JOKHCqYYPl Ml[yNlQyPjN{M{C=
PC3 M3nndGZ2dmO2aX;uJGF{e2G7 Mkf2NE0yODBibl2= MX:yOEBp NX;DVYtne3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> MWeyOFE3OzJ|MB?=
PC3-AR NWjFRWJRTnWwY4Tpc44hSXO|YYm= NUXxe4JvOC1zMECgcm0> NXTDVJdSOjRiaB?= MlzWd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= NI\ifJQzPDF4M{KzNC=>
OS-RC-2 NUTxSFRFS2WubDDWbYFjcWyrdImgRZN{[Xl? MoG1NE0yODByIH7N NY\TZVJGOjRxNEivO|IhcA>? NUCwUFhpTE2VTx?= M4C2bIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mkn0NlQyPDR5M{e=
OS-RC-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fHXFUxKG6P MXW0PEBp NXvBOW1kTE2VTx?= NH\wZXhqdmS3Y3XzJGczN01iYYLy[ZN1 MkDxNlQyPDR5M{e=
OS-RC-2 NVzae21OSXCxcITvd4l{KEG|c3H5 M3zKVVUxKG6P NVvKOIx{PDhiaB?= MU\EUXNQ NW\j[HVrcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M37TXlI1OTR2N{O3
SK-N-AS NHvEcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfWO29TOOLCk{iwJI5O MYS0PEBp MXvJR|UxRTJ5LkSgcm0> NYTjZYdXOjRyOUi3PVk>
SK-N-DZ Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTN[oIx6oDVOECgcm0> M4XKfFQ5KGh? MlfOTWM2OD1{MT65JI5O M2P6S|I1ODl6N{m5
SK-N-SH MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fFeVDjiJN6MDDuUS=> MUC0PEBp NHzhUpVKSzVyPUeyMlMhdk1? MkXENlQxQTh5OUm=
SK-N-BE M2\jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqw5qCUQDBibl2= MV20PEBp NXKzZ5lQUUN3ME23OU41KG6P NInk[oIzPDB7OEe5PS=>
SK-N-AS Mn;sRZBweHSxc3nzJGF{e2G7 MWWw5qCUQDBibl2= NF3MO3Y1QCCq NUDGfmZZeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v M1XvbVI1ODl6N{m5
SK-N-DZ MnrQRZBweHSxc3nzJGF{e2G7 NFfpRpQx6oDVOECgcm0> NYK4cI9CPDhiaB?= MWDwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= MoPCNlQxQTh5OUm=
SK-N-SH MVXBdI9xfG:|aYOgRZN{[Xl? MUKw5qCUPDBibl2= MmOwOFghcA>? M17RbpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> MUCyOFA6QDd7OR?=
SK-N-BE M1;lSmFxd3C2b4Ppd{BCe3OjeR?= NY\jRXRIOOLCk{SwJI5O NX3neY5VPDhiaB?= MXvwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= M4fTclI1ODl6N{m5
SK-N-AS NUD3VIpTTnWwY4Tpc44hSXO|YYm= MYSw5qCUQDBibl2= NIHMcYo1QCCq MlHEbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NXPMSZN3OjRyOUi3PVk>
SK-N-DZ NXi5Nmd7TnWwY4Tpc44hSXO|YYm= NHPLN4kx6oDVOECgcm0> NF2wb|Q1QCCq NVvZTXpQcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? Ml7NNlQxQTh5OUm=
SK-N-SH MYXGeY5kfGmxbjDBd5NigQ>? NH3jPGwx6oDVNECgcm0> MoX3OFghcA>? NUjGdXZbcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MWGyOFA6QDd7OR?=
SK-N-BE NX33Z45kTnWwY4Tpc44hSXO|YYm= M4nISlDjiJN2MDDuUS=> NIXw[5E1QCCq M3HWRolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MXeyOFA6QDd7OR?=
HCC-LM3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnuSJYyNTFyMECgcm0> MlLCNlQwPDhxN{KgbC=> NVzsUoFQTE2VTx?= M1HVVYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIL3VVQzPDB7M{m1Oi=>
HepG2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPZT48yNTFyMECgcm0> NULRVYhDOjRxNEivO|IhcA>? NWO1doxSTE2VTx?= M3qyd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIPD[WkzPDB7M{m1Oi=>
SMMC-7721 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfDNU0yODByIH7N NFXrTZIzPC92OD:3NkBp MYPEUXNQ MlTIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2XjblI1ODl|OUW2
HCC-LM3 MnOzRZBweHSxc3nzJGF{e2G7 MVi1NEBvVQ>? NVzXcZlyPDhiaB?= NF7s[ZlFVVOR M3rzNolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 MY[yOFA6Ozl3Nh?=
HepG2 M2TNTGFxd3C2b4Ppd{BCe3OjeR?= NEXFeXk2OCCwTR?= NEfQWmU1QCCq MVzEUXNQ MojEbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> MkjzNlQxQTN7NU[=
SMMC-7721 M2rn[GFxd3C2b4Ppd{BCe3OjeR?= MWW1NEBvVQ>? MlHkOFghcA>? MXvEUXNQ MnfWbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> NYL4epgxOjRyOUO5OVY>
HCC-LM3 MnHNSpVv[3Srb36gRZN{[Xl? MoDkOVAwOTByIH7N MlHvNlQhcA>? NXzMdlZMTE2VTx?= MX\k[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi M363eVI1ODl|OUW2
HepG2 M2fWfWZ2dmO2aX;uJGF{e2G7 MonSOVAwOTByIH7N NEDRcoMzPCCq NXTzXFNxTE2VTx?= M4raTYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= NGq1VWszPDB7M{m1Oi=>
SMMC-7721 MWPGeY5kfGmxbjDBd5NigQ>? M3LyXlUxNzFyMDDuUS=> M3ewZ|I1KGh? NFvrSpJFVVOR NFnC[ohl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg MUKyOFA6Ozl3Nh?=
HCC-LM3 NVHWd2NbTnWwY4Tpc44hSXO|YYm= M4fVTlUxNzFyMDDuUS=> NGXac|czPCCq M120TWROW09? M3XJcYRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? MXGyOFA6Ozl3Nh?=
HepG2 Ml7RSpVv[3Srb36gRZN{[Xl? MYG1NE8yODBibl2= Mn3SNlQhcA>? MmPuSG1UVw>? M1PQV4Rwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? NH\3XGMzPDB7M{m1Oi=>
SMMC-7721 M4OxTWZ2dmO2aX;uJGF{e2G7 M1f0XVUxNzFyMDDuUS=> MoC3NlQhcA>? MVjEUXNQ NXPJZ2VD\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= M{TydFI1ODl|OUW2
FaDu M37HNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DQZVExOOLChX7N MlLqPE8yOC9zMjDo MVXkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? NF7oRVkzPDB{NkS4Ni=>
FaDu NIm0cnNHfW6ldHnvckBCe3OjeR?= NUfwV|A5OTBy4pEFcm0> M3LMc|IwPC96L{GyJIg> NU[yOlN[cW6mdXPl[EBxOjGZYX[xM2NqeDIEoHX4dJJme3Orb36= MnLNNlQxOjZ2OEK=
PC-3  M2HFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTOcmFQOC1zMDFOwG0> M2XkNFI1NzR6L{eyJIg> NFfLe|BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYKyN|k6OTJzNh?=
LNCaP MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK3NE02KM7:TR?= NYHZ[GxkOjRxNEivO|IhcA>? M4DobolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MljXNlM6QTF{MU[=
RWPE-1  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO1NE0zOCEQvF2= NXPSTGpbOjRxNEivO|IhcA>? MVHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1T2R|I{QTlzMkG2
Capan-1 NVrRSJdKTnWwY4Tpc44hSXO|YYm= M3\XO|I2NzVyL{GwNEBvVQ>? NF;velk5NzJ2L{S4JIg> NHvzPGxFVVOR NFLVWJpld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n NGjUSFAzOzl{Mki4Oi=>
L3.6pl NWfR[YJETnWwY4Tpc44hSXO|YYm= NFfWcJYzPS93MD:xNFAhdk1? MXe4M|I1NzR6IHi= NFPEdIJFVVOR MlrS[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= MoroNlM6OjJ6OE[=
CFPAC-1  MYnGeY5kfGmxbjDBd5NigQ>? MUeyOU82OC9zMECgcm0> M4TBUlgwOjRxNEigbC=> MXTEUXNQ NEfBbmVld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n M{Da[|I{QTJ{OEi2
Capan-1 NFO5TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXPPY0zPS93MD:xNFAhdk1? NXHwfFZYPDhiaB?= MoP4SG1UVw>? NFfETFNz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVz0bJlXOjN7MkK4PFY>
L3.6pl MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;zdGozPS93MD:xNFAhdk1? MXO0PEBp MnfsSG1UVw>? MVHy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1fhR|I{QTJ{OEi2
CFPAC-1  NV7Fd4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnFNlUwPTBxMUCwJI5O MoD6OFghcA>? NIfwV2ZFVVOR NWLkdoc1emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVSyN|kzOjh6Nh?=
Capan-1 MX;BdI9xfG:|aYOgRZN{[Xl? MYOyOU82OC9zMECgcm0> MVu0PEBp NVPEfo0xTE2VTx?= NFX1WIhqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYq3eZF7OjN7MkK4PFY>
L3.6pl MkTMRZBweHSxc3nzJGF{e2G7 M17RdFI2NzVyL{GwNEBvVQ>? Mn3rOFghcA>? NXW3c5NXTE2VTx?= M2D4OIlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVGyN|kzOjh6Nh?=
CFPAC-1  M3;uU2Fxd3C2b4Ppd{BCe3OjeR?= M3vHU|I2NzVyL{GwNEBvVQ>? MYO0PEBp M37DTWROW09? MYfpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1rVUVI{QTJ{OEi2
HN22 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLhVYlrOC1{MDDuUS=> MV2yOE81QCCq NX:4VVA4TE2VTx?= M3TGS4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> M2GyZVI{QDd5MkO1
HSC4  M2rxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTPNE0zOCCwTR?= NUTDRXZVOjRxNEigbC=> NHPDdHFFVVOR MoD5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NFnsXowzOzh5N{KzOS=>
HN22 NEHTVHdCeG:ydH;zbZMhSXO|YYm= M2W1W|AuOjBibl2= MlrYOFghcA>? MUTEUXNQ M3jTbIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGrSW3kzOzh5N{KzOS=>
HSC4  MUTBdI9xfG:|aYOgRZN{[Xl? NF;jVZYxNTJyIH7N MVi0PEBp NI\5VIRFVVOR MUnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXTQWJZWOjN6N{eyN|U>
HN22 NEXBTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnkT2sxNTJyIH7N M4fBTlQ5KGh? M32xXmROW09? M1nkWYlv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> M3;sSVI{QDd5MkO1
HSC4  M4L4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHzZZR{OC1{MDDuUS=> NWLVXGppPDhiaB?= MoHpSG1UVw>? NVLlRnVPcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh M{\QTVI{QDd5MkO1
HN22 MnfsSpVv[3Srb36gRZN{[Xl? M4HsOlAuOjBibl2= NETJTHM1QCCq MVHEUXNQ MkKyd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg M3PPfFI{QDd5MkO1
HSC4  MX7GeY5kfGmxbjDBd5NigQ>? M1jyZlAuOjBibl2= MnfwOFghcA>? NEPNZ3dFVVOR MmTod5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg MkPENlM5Pzd{M{W=
Cal62 M1;xVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[zTWM2OD1|MzFCtUA1KG6P NVWyfWJnOjN6MkSwOlQ>
Hth7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF3INMxJFIhdk1? NI[zVVEzOzh{NEC2OC=>
Hth83 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4TWM2OD1|NDFCtUA2KG6P NFPNPIwzOzh{NEC2OC=>
C643 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTdzINMxJFExKG6P MUiyN|gzPDB4NB?=
SW1736 NV;M[o9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPZRoVKSzVyPUO1JOKyKDhibl2= MlvXNlM5OjRyNkS=
T241 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Tpe2lEPTB;NkWgxtEhPyCwTR?= M3HEXVI{QDJ2ME[0
T351 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEmzcZlKSzVyPUWwJOKyKDFyIH7N MnP3NlM5OjRyNkS=
BHP2-7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TMVmlEPTB;M{egxtEhPiCwTR?= NELNV5AzOzh{NEC2OC=>
T238 NU\3XnRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n0OmlEPTB;MTy1NFAhyrFiMkCwJI5O NY\QeXM5OjN6MkSwOlQ>
HCT8 M3HwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT3N2lXPzJiaB?= NG\NVndFVVOR NHLjT3dKSzVyPUGyMlnjiIoEsfMAjVEvQSCwTR?= MY[yN|I6QTN6OB?=
H630 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TjW|czKGh? MVvEUXNQ Ml;OTWM2OD1zMj605qCKyrIkgJmzMlEhdk1? NYGyeGI6OjN{OUmzPFg>
cH630 5-FU-res M{HoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:yZlczKGh? MnT3SG1UVw>? NYrzdGpDUUN3ME2xOU426oDLwsJihKkyNjJibl2= MnXZNlMzQTl|OEi=
HCT116 M4P6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;rfGpNPzJiaB?= M4jaRmROW09? M1XteWlEPTB;MUCuO-KBkcLz4pEJNk4zKG6P M{PtbVI{Ojl7M{i4
HCT116 p53−/− NIrZS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm4boZqPzJiaB?= M3v3NWROW09? M4r2[GlEPTB;OD625qCKyrIkgJmxMlchdk1? NUTHTow3OjN{OUmzPFg>
dHCT116 p21−/− MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7L[JY4OiCq MnK3SG1UVw>? M37aOGlEPTB;NT655qCKyrIkgJmxMlMhdk1? MlHmNlMzQTl|OEi=
HT29 NXPxfFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3UO|IhcA>? NEfTe2dFVVOR MoXETWM2OD1zNj6z5qCKyrIkgJmyMlMhdk1? MXiyN|I6QTN6OB?=
LoVo M3Xwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy3NkBp MVnEUXNQ MV;JR|UxRTVwMfMAjeKy6oDLMD62JI5O NEfDfJozOzJ7OUO4PC=>
RKO MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3iyZ|czKGh? NWjMTmdLTE2VTx?= Ml3KTWM2OD15LkpihKnDueLCiUKuNkBvVQ>? MknqNlMzQTl|OEi=
SW480 M1XGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;oO|IhcA>? NGr6R|dFVVOR MmLJTWM2OD1zNz615qCKyrIkgJmwMlghdk1? M2fFOVI{Ojl7M{i4
eSW620 NESx[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[3NkBp MXrEUXNQ NX3rT4tZUUN3ME25MlHjiIoEsfMAjVIvOSCwTR?= M3jNelI{Ojl7M{i4

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02032810 Active not recruiting Melanoma|Skin Cancer H. Lee Moffitt Cancer Center and Research Institute|Novartis January 7 2014 Phase 1
NCT03256045 Recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma University of Washington|National Cancer Institute (NCI) May 31 2018 Phase 2
NCT01169636 Completed Hodgkin''s Lymphoma M.D. Anderson Cancer Center|Novartis January 31 2011 Phase 1|Phase 2
NCT02676323 Recruiting Acute Myeloid Leukemia|Myelodysplastic Syndrome St. Jude Children''s Research Hospital May 3 2016 Phase 1
NCT02717455 Recruiting Glioma Pediatric Brain Tumor Consortium June 28 2016 Phase 1
NCT01301807 Active not recruiting Non-Secretory Plasma Cell Myeloma|Plasmacytosis|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma M.D. Anderson Cancer Center|National Cancer Institute (NCI) July 28 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID